title: Successful treatment of blepharitis with bibrocathol (Posiformin® 2 %).
abstract: BACKGROUND
  Bibrocathol is a well-established antiseptic drug for the treatment of acute eyelid diseases like blepharitis. Despite its frequent use in clinical practice, no controlled clinical trial on the efficacy of bibrocathol 2% eye ointment has been performed until now. The aim of the study was to investigate efficacy, safety and tolerability of bibrocathol (Posiformin® 2 %) eye ointment in patients diagnosed with blepharitis.
  
  
  METHODS
  In this multi-center, randomized, double-masked, placebo-controlled parallel-group comparison, the change of signs and symptoms (sum score) of blepharitis in 197 patients (ITT (intention-to-treat-group); mean age 56 ± 18 years, 56 % female, active drug:vehicle = 97:100) over 2 weeks treatment with bibrocathol 2 % eye ointment was evaluated.
  
  
  RESULTS
  Patients receiving bibrocathol 2 % showed greater improvement in the sum score than the placebo patients (p < 0.0001, Cohen's effect size d = 0.73). Also, the results from further efficacy assessments improvement of single symptoms and ocular discomfort measured by a VAS (visual analogue scale) supported treatment with bibrocathol. Patients and investigators provided favorable tolerability ratings preferring bibrocathol over placebo. No safety issues were observed with regard to intraocular pressure, visual acuity, or occurrence of adverse events.
  
  
  CONCLUSIONS
  Blepharitis therapy with the antiseptic bibrocathol 2 % in this trial was highly efficacious and safe.
authors.affiliation: Department of Ophthalmology, Kharkov District Clinical Hospital, Kharkov, Ukraine.
authors.forename: Pavel A
authors.initials: PA
authors.lastname: Bezdetko
authors.forename: Nikolai
authors.initials: N
authors.lastname: Sergienko
authors.forename: Yuriy
authors.initials: Y
authors.lastname: Dyomin
authors.forename: Andrei
authors.initials: A
authors.lastname: Korol
authors.forename: Nik
authors.initials: N
authors.lastname: Nikitin
authors.forename: Matthias
authors.initials: M
authors.lastname: Merzbacher
authors.forename: Dorothea
authors.initials: D
authors.lastname: Groß
authors.forename: Ralf
authors.initials: R
authors.lastname: Kohnen
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000009:adverse effects / Q000627:therapeutic use*; D001762:Blepharitis / Q000188:drug therapy*; D002396:Catechols / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000891:Anti-Infective Agents, Local; D002396:Catechols; D009824:Ointments; C006748:bibrocathol